Introduction {#sec1-1}
============

Globally, tuberculosis stands amongst top 10 causes of untimely deaths. In 2018, tuberculosis (TB) caused an approximately 1.5 million deaths amongst human immunodeficiency virus (HIV)-negative people, in addition, there were 251,000 deaths among HIV-positive population. India is one of the top eight countries that accounts for nearly two-thirds of the new TB cases of the globe. In 2018, worldwide, there were an estimated 484,000 new rifampicin (RIF)-resistant tuberculosis cases[@ref1]. India topped again as it harboured 24 per cent of global drug-resistant (DR)-TB burden. In India, in 2018, an estimated 27 lakh new TB cases were reported and 4.5 lakh cases had died. An estimated one million TB cases, in India, either remained undiagnosed or unreported[@ref1][@ref2].

Approximately, 21 per cent cases were of extrapulmonary tuberculosis (EPTB) that included meningeal tuberculosis as well[@ref3]. The global burden of EPTB ranges from 8-24 per cent of all TB cases[@ref4]. The exact prevalence of central nervous system (CNS) TB in India is not precisely known. As per a rough estimate, approximately one per cent of all cases of TB suffer from CNS-TB[@ref5]. TBM is the most common type of CNS-TB. Report from a north Indian Centre, located in a very high TB burden region, noted that amongst 306 cases of CNS-TB, 214 (69.9%) had TBM. In 62 (20.26%) patients, TBM was a part of widely disseminated TB. Ten cases had MDR TBM[@ref6]. Approximately, half of the CNS-TB cases either die or become severely disabled[@ref7] as it is associated with five-times more risk of death[@ref8].

TBM is diagnosed easily on clinical grounds, but it is difficult to confirm microbiologically. In roughly 50 per cent of cases a definitive microbiologic diagnosis is not achieved, and physician has to start empirical anti-tuberculosis treatment (ATT). Several infective and non-infective CNS disorders closely mimic TBM, such as partially treated pyogenic meningitis, fungal meningitis, sarcoidosis, meningeal metastases and meningeal lymphomatosis. All these conditions may pose a formidable diagnostic challenge in many patients.

TBM is a paucibacillary disease, and it is often difficult to isolate *Mycobacterium tuberculosis* (MTB) in cerebrospinal fluid (CSF) by conventional methods. Since the past decade, a sea change in the diagnostics of TBM has taken place. Genotypic tests have led to a rapid identification of MTB that to in a higher proportion of CSF specimens. Conventional drug susceptibility testing takes an unacceptably long time for definite results. In India, DR-TBM is also frequently encountered. Isoniazid (INH) mono-resistance is the most common form of drug resistance seen in TBM[@ref9]. Multidrug-resistant TBM is potentially life-threatening and needs a prompt diagnosis. In isolated patients, extensive drug-resistant (XDR) TBM has also been identified[@ref9][@ref10]. This review focuses on the current global and Indian status of TBM diagnostics.

Phenotypic tests {#sec1-2}
================

Conventional tests, microscopy for acid-fast bacilli (AFB) and MTB culture in CSF, are the classical tests that are conventionally used to confirm bacteriological diagnosis. Ziehl-Neelsen (Z-N) staining of CSF sediments and microscopy, to detect (AFB), has long been the mainstay of the diagnosis of TBM. The sensitivity of microscopy is abysmally low. Yield from microscopy ranges from 10 to 20 per cent and can marginally be increased if a large volume of CSF is processed. Fluorescence microscopy is slightly more sensitive than conventional Z-N microscopy. However, fluorescence microscopy requires considerable technical expertise[@ref9][@ref10].

MTB culture has always been the gold standard for the diagnosis of TBM. It also detects drug resistance. MTB culture is performed on either a solid or a liquid medium. The yield of culture positivity is much higher for liquid culture system (BACTEC Mycobacteria Growth Indicator Tube system) than solid (Lowenstein-Jensen) culture. MTB culture, to yield a positive result, takes approximately 8-10 days in liquid medium and up to eight weeks on solid medium. The sensitivity of mycobacterial culture is around 40-50 per cent[@ref9]. Liquid culture is slightly more sensitive test[@ref9]. In a large Vietnamese study, that enrolled 545 TBM patients, with the objective to assess the role of corticosteroids, microbiological confirmation could be achieved in only 36 per cent cases. In this study, only conventional phenotypic tests were used[@ref11] ([Table I](#T1){ref-type="table"}). In a reanalysis of four TBM studies done in Vietnam from 2004 to 2016, that included 1048 patients microbiological confirmation could be done in 50 per cent HIV-uninfected and 70 per cent HIV-infected TBM cases. In all four studies, Xpert MTB/RIF assay was one of the tests that had been used[@ref23] ([Table II](#T2){ref-type="table"}).

###### 

Tests used for detection of *Mycobacterium tuberculosis* (MTB) in cerebrospinal fluid and identifying drug resistance

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
   Phenotypic tests
  Smear microscopy
   Ziehl-Neelsen stains
   AFB auramine O or auramine-rhodamine stains fluorescence microscopy
  Culture
   Solid culture L-J medium
   Liquid culture system like Mycobacteria Growth Indicator Tube (BACTEC™ MGIT 960™ TB System)
   (The liquid culture systems are more rapid than conventional solid culture system)
  Genotypic tests
   IS*6110* PCR[@ref12]
   IS*6110* is highly conserved part of *M. tuberculosis* complex genome and is specific for MTB complex
    Simple PCR
    Real-time PCR
    Multiplex PCR
  Multitargeted (LAMP)[@ref13][@ref14]
   GeneXpert MTB/RIF assay[@ref15][@ref16]
    Cartridge-based technology that simultaneously detects MTB complex and RIF resistance
   GeneXpert Ultra (Ultra)[@ref17][@ref18]
    Xpert MTB/RIF Ultra is a new technology for faster detection of MTB complex and RIF resistance
   Molecular line probe assays[@ref19]
    Line probe assays are strip-based technology meant for rapid detection of MTB complex and RIF and INH resistance
   Commercial line probe assay system
    INNO-LiPA RIF TB (Innogenetics, Ghent Belgium)
    The GenoType MTBDR (Hain Life Sciences, Gmbh, Nehren Germany)
   Other tests
  The IGRAs[@ref20][@ref21]
   IGRAs are not recommended for diagnosis of tuberculous meningitis
  Commercial IGRAs
   An ELISPOT evaluates the release of IFN-γ from T lymphocytes following stimulation of the cells with MTB-specific antigens
   QuantiFERON^®^ TB Gold test (Cellestis Ltd., Carnegie, Victoria, Australia) and the T-SPOT^®^ TB IGRAs (Oxford Immunotec, Oxford, United Kingdom) are other commercially available IGRAs
  LAM lateral flow assay[@ref22]
   This test has a very low sensitivity in the CSF
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

L-J, Löwenstein-Jensen; PCR, polymerase chain reaction; LAMP, loop-mediated isothermal amplification; IGRAs, interferon-gamma release assays; ELISPOT, enzyme-linked immunospot test; IFN-γ, interferon-γ; LAM, lipoarabinomannan; CSF, cerebrospinal fluid; RIF, rifampicin; INH, Isoniazid; MTBDR, *Mycobacterium tuberculosis* drug-resistant; AFB, acid-fast bacilli

###### 

Sensitivity of various phenotypic and genotypic tests and drug resistance pattern in tuberculous meningitis \[studies reported from various countries (except India) published after 2010\]^\*^

  Reference                         Country                               Number of patients                Type of study                    Bacteriologically confirmed   Microscopy        Solid culture               Liquid culture    PCR              Line- probe assay   Xpert MTB/RIF                                                Xpert MTB/RIF Ultra   RIF/INH resistance      Lipoarabinomannan
  --------------------------------- ------------------------------------- --------------------------------- -------------------------------- ----------------------------- ----------------- --------------------------- ----------------- ---------------- ------------------- ------------------------------------------------------------ --------------------- ----------------------- ------------------------------------------------------------------------------------------------
  Siddiqi *et al*, 2019[@ref24]     Zambia                                550; 474 (86.2%) with HIV         Prospective                      19.1% (105/550)               NA                107 HIV-=12.3% HIV+=20.5%   NA                NA               NA                  Overall 10% (55/550) with MTB in CSF HIV-=52.9% HIV+=94.2%   NA                    11% (6/55)              Overall 4.2% (23/550) with MTB in CSF CSF HIV-=21.9% HIV+=94.2% Urine LAM HIV-=24.1% HIV+=6.1%
  Heemskerk *et al*, 2018[@ref25]   Vietnam, South Africa and Indonesia   618; 194 (31.3%) with HIV         Prospective                      28.2% (174)                   33.9% (129/380)   NA                          31.8% (119/374)   NA               NA                  25.1% (95/379)                                               NA                    NA                      NA
  Metcalf *et al*, 2018[@ref26]     Peru                                  37; 23 (62%) with HIV             Prospective                      23% (8/37)                    7%                NA                          23% (7/37)        NA               NA                  23% (8/37)                                                   NA                    38% (3/8)               NA
  Chaidir *et al*, 2018[@ref27]     Indonesia                             1180; 203 (18.3%) with HIV        Prospective                      42.2% (501)                   12.2% (86/703)    46% (163/354)               48.8% (332/680)   64% (212/331)    NA                  42% (73/174)                                                 NA                    NA                      NA
  Bahr *et al*, 2015[@ref28]        Uganda                                107; 105 (98.1%) with HIV         Prospective                      17% (18) all with HIV         3.7% (4/107)      NA                          11% (12/107)      NA               NA                  16.8% (18/107)                                               0                     0                       NA
  Solomons *et al*, 2015[@ref29]    South Africa                          55 children; 8 (14.5%) with HIV   Prospective                      24% (13)                      3.6% (2/55)       NA                          22% (12/55)       NA               33% (18/55)         26% (14/55)                                                  NA                    inhA mutation in 1      NA
  Patel *et al*, 2014[@ref30]       South Africa                          91; 78 (85.7%) with HIV)          Prospective                      34% (31/91)                   NA                NA                          34% (31/91)       22% (20/91)      NA                  21% (19/91)                                                  NA                    NA                      NA
  Nhu *et al*, 2014[@ref31]         Vietnam                               379                               Retrospective                    40% (151/379)                 78.6% (143/182)   NA                          66.5% (121/182)   NA               NA                  59.3% (108/182)                                              NA                    3.7% (4/109) by Xpert   NA
  Patel *et al*, 2013[@ref32]       South Africa                          123; 108 (87.8%) with HIV         Prospective                      48% (59/123)                  5.7% (7/123)      NA                          40% (49/123)      22.7% (28/123)   NA                  19.5% (24/123)                                               NA                    NA                      NA
  Chaidir *et al*, 2012[@ref33]     Indonesia                             207; 37 (17.9%) with HIV          Retrospective (stored samples)   50.7% (105/207)               1.4% (3/207)      NA                          49.2% (102/207)   68% (140/207)    NA                  NA                                                           NA                    NA                      NA

^\*^In 2010, World Health Organization approved Xpert MTB/RIF test for diagnostic use. HIV, human immunodeficiency virus; NA, not available; MTB/RIF, *Mycobacterium tuberculosis*/rifampicin

In India, in majority of centres, conventional tests still remain the mainstay of tuberculous diagnostics. In a large number of Indian patients, diagnosis of TBM remains unconfirmed. In a tertiary care centre having all modern facilities, microbiological confirmation was possible in only in 36 per cent (43/118) of patients. In this study, culture was positive only in one patient, and Ziehl-Neelsen microscopy was positive in three cases only[@ref34] ([Table III](#T3){ref-type="table"}).

###### 

Sensitivity of various phenotypic and genotypic tests and drug resistance pattern in tuberculous meningitis (Indian data)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                         Number of patients   Bacteriologically confirmed   Sensitivity of different tests                          Resistance pattern
  ---------------------------------- -------------------- ----------------------------- ------------------------------------------------------- ------------------------
  Sharma *et al*, 2018[@ref35]       180                  80                            Xpert=91 (50.5%)\                                       RIF resistance=14
                                                                                        PCR=157 (87.2%)                                         

  Manke *et al*, 2017[@ref36]        20                   7                             PCR=12                                                  NA

  Rufai *et al*, 2017[@ref37]        267                  52 (19.5%)                    Liquid culture=52 (19.5%)\                              RIF resistance=(10.5%)
                                                                                        Xpert MTB/RIF=38 (14.2%)                                

  Kumar *et al*, 2016[@ref38]        698 CSF samples      176 (25.2%)                   Liquid culture=176 (25.2%)\                             57 (32.4%) with 5 MDR
                                                                                        ELISA=61 (34.7% of culture positive)                    

  Bhatia *et al*, 2016[@ref39]       34                   \-                            Liquid culture=5 (14.7%)\                               NA
                                                                                        Xpert MTB/RIF=13 (38%)                                  

  Gupta *et al*, 2015[@ref19]        238                  78                            Microscopy=5 (2.1%)\                                    5 MDR 9 isoniazid
                                                                                        Liquid culture=78 (32.7%)\                              
                                                                                        PCR=30 (12.6%)\                                         
                                                                                        Geno Type MTBDRplus Assay=31 (13%)                      

  Panagariya *et al*, 2013[@ref40]   50                   11                            Microscopy=2 (1%) Liquid culture=9 (18%) PCR=34 (68%)   NA

  Haldar *et al*, 2012[@ref41]       194                  29                            Liquid culture=29 (14.9%)\                              NA
                                                                                        PCR=66%                                                 

  Sharma *et al*, 2010[@ref42]       70                   10                            Microscopy=1 (1.4%)\                                    NA
                                                                                        Liquid culture=10 (14.3%)\                              
                                                                                        PCR=58 (82.8%)                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

ELISA, enzyme-linked immunosorbent assay; MDR, multidrug-resistant tuberculosis

Genotypic tests {#sec1-3}
===============

Genotypic tests utilize transcription-mediated amplification of a portion of the genome-specific to the MTBcomplex, enabling identification the bacilli in cerebrospinal fluid. Genotypic tests also detect mutations in genes that are known to be associated with anti-tuberculosis drug resistance. Genotypic methods are rapid and have higher sensitivity and specificity ([Table I](#T1){ref-type="table"}).

 {#sec2-1}

### Polymerase chain reaction (PCR) {#sec3-1}

The PCR is a simple technology meant for rapid identification of MTBgenome in the cerebrospinal fluid. In PCR methods, with the help of nucleic acid amplification technique, portions of MTB genome are amplified. PCR usually targets IS*6110* gene sequence, which is specific for MTB complex. Several other MTB DNA-specific sequences such as protein antigen B, MPB64 and 65 kDa are also targeted. Multiplex polymerase chain targets two genes simultaneously. Nested PCR technology is a two-step process. The first stage amplification is done with primers that focus on the target sequence. In the second step, the amplification process takes place on the products of the first amplification, with primers that bind to the target genome sequence. Nested PCR technique is more specific because it avoids non-specific amplification of the DNA template. Real-time PCR quantitatively assesses the amount of the PCR product in real time. These assays are highly accurate and reproducible.

A systematic review and meta-analysis demonstrated that commercial nucleic acid amplification tests had a sensitivity of 56 per cent and specificity of 98 per cent[@ref12]. In the 35 studies with in-house developed tests, accuracy could not be established, because of a wide variability in test results. PCR assays are considered to have a confirmatory role in the diagnosis of TBM diagnosis, however, because of low sensitivity lack behind to rule out tuberculous meningitis with certainty[@ref12]. Real-time PCR assay, with overall sensitivity of 86 per cent, in TBM is now preferred PCR technique[@ref43].

### Multi-targeted loop-mediated isothermal amplification (LAMP) {#sec3-2}

The LAMP is an isothermal DNA amplification method that uses two or three sets of primers to promptly multiply very small quantities of DNA. In this method, amplification procedures take place in a tube, which contains all the required material (buffer, target DNA, DNA polymerase and primers). The amplified DNA can be assessed with naked eyes. The biggest advantage of TB LAMP is that this technique needs minimal laboratory infrastructure and has limited biosafety hazards. In addition, LAMP is economical, that makes this test ideal for Indian conditions.

LAMP is currently being used in pulmonary TB. Its diagnostic role in EPTB is not clear. A meta-analysis showed a pooled sensitivity of 77 per cent and specificity of 99 per cent for LAMP in EPTB[@ref13]. LAMP has also been employed in CSF specimens. This test had a sensitivity and specificity of 96 and 100 per cent respectively for confirmed (50 culture positive) TBM cases. The sensitivity in probable TBM was 82 per cent. The overall sensitivity was 88 per cent and the specificity was 100 per cent[@ref14].

### Xpert MTB/RIF assay {#sec3-3}

Xpert MTB/RIF assay (Cepheid, USA) is a fully automated, cartridge-based nucleic acid amplification technology, which simultaneous detects MTB bacilli and RIF resistance, directly in CSF specimens. GeneXpert MTB/RIF assay is a commercial, real-time PCR-based technique. Results of this assay are available within two hours. This assay detects mutations responsible for RIF resistance. The WHO recommended the use of Xpert MTB/RIF assay in 2010. Since 2013, it has also been recommended for use in all forms of EPTB, including TBM[@ref15]. Under the Revised National Tuberculosis Control Programme (RNTCP), Xpert MTB/RIF technology is now widely available in India[@ref2].

Xpert MTB/RIF is being extensively used in Vietnam, Indonesia Uganda and South Africa. Even in developed counties, this is a frontline test for TBM. Xpert MTB/RIF results for 740 CSF specimens from 698 patients, in England, were compared with that of culture. The overall sensitivity of Xpert MTB/RIF test was 55 per cent and specificity was almost 100 per cent[@ref16]. Value of Xpert MTB/RIF was assessed in two Indian studies. Rufai *et al*[@ref37] noted a lower sensitivity of Xpert MTB/RIF than liquid culture. In a collection of 267 CSF specimens (52/19.5% culture positive), Xpert MTB/RIF assay was positive only in 38 (14.2%) specimens. In the second study, Sharma *et al*[@ref35] demonstrated positive Xpert MTB/RIF test in 50 per cent (91/180) cases. Multiplex PCR technique demonstrated better sensitivity (157/180; 87.2%).

*Xpert MTB*/RIF Ultra {#sec1-4}
=====================

Xpert MTB/RIF Ultra is an advancement of Xpert MTB/RIF technology with greater sensitivity. Xpert MTB/RIF Ultra is able to detect MTB bacilli even if present in low numbers in clinical specimens. Technological advancement, in Xpert MTB/RIF Ultra, is basically in its cartridge. Ultra-cartridge accommodates a large volume of CSF. Two additional molecular targets have been added to the platform, to accurately identify MTB bacilli and RIF resistance[@ref44]. The WHO recommends Xpert Ultra as the first diagnostic test in TBM[@ref17].

Several studies have consistently demonstrated the value of ultra-technology in the diagnostics of TBM. A prospective cohort of 204 HIV-positive patients was evaluated for TBM. Uniform clinical case definition identified 51 patients, as probable/possible cases. Among these probable/definite cases, Xpert MTB/RIF Ultra had 76 per cent sensitivity compared with Xpert 56 per cent or culture 61 per cent. Xpert MTB/RIF Ultra was able to confirm nine TBM cases that were missed both by Xpert and culture[@ref45]. In another study, Xpert MTB/RIF Ultra was evaluated in 129 HIV-positive patients of suspected TBM. Twenty three patients were classified as probable or definite tuberculous meningitis. Xpert Ultra sensitivity was 70 per cent compared with 43 per cent by Xpert and 43 per cent by culture. Eight patients were only positive by Xpert Ultra[@ref46]. This technology is being considered a game-changer in the diagnostics of TBM; however, more data from HIV-negative patients are needed to further establish its value[@ref18].

 {#sec2-2}

### Line probe assay {#sec3-4}

The line probe assay is a strip-based technology that has sufficient sensitivity and specificity to promptly identify RIF and INH drug resistance in MTB isolates. The GenoType MTB DRplus test is one of the commercially available techniques that identifies mutations in *rpoB*, *katG* and *inhA* promoter genes. GenoType MTBDRplus line probe assay has almost no role in the identification of MTB and drug resistance, directly in CSF samples ([Table IV](#T4){ref-type="table"}).

###### 

Differences between GenoType MTBDRplus line probe assay and Xpert MTB/RIF assay

  Line probe assay                                                                                                          Xpert MTB/RIF
  ------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------
  *Mycobacterium tuberculosis* isolates or AFB-positive samples                                                             Directly performed on clinical samples Initial test for tuberculous meningitis
  Diagnose MDR TB                                                                                                           Identifies *M. tuberculosis* and diagnoses drug resistance
  Detects RIF and INH resistance                                                                                            Detects RIF resistance only
  It takes two to three days for positive results                                                                           It takes three to four hours for positive results
  DNA strip technology                                                                                                      Cartridge based technology
  It is a multiplex PCR in combination with reverse hybridization-based technique                                           It is an RT-PCR-based assay
  Suitable for use at national/central reference laboratories                                                               Xpert MTB/RIF suitable for public health settings as well
  Commercial kits INNO-LiPA RIF TB (Innogenetics, Ghent, Belgium) GenoType MTBDRplus (Hain Life-Science, Nehren, Germany)   Xpert MTB/RIF (Cepheid Sunnyvale, USA)

RT-PCR, reverse transcription polymerase chain reaction *Source*: Refs [@ref47][@ref48]

A study from northern India evaluated GenoType MTBDRplus line probe assay for early identification of drug resistance in MTB isolates recovered from CSF samples of confirmed TBM patients[@ref19]. Using BACTEC mycobacterial growth indicator tube drug sensitivity testing as a gold standard, the sensitivity and specificity of GenoType MTBDRplus line probe assay for INH resistance were 93 and 97 per cent, respectively. For RIF resistance, sensitivity and specificity figures were 80 and 98.8 per cent, respectively. The line probe assay could detect MTB only in 55 per cent of CSF confirmed TBM samples[@ref19]. More data are needed to establish the precise role of the line probe assays in the diagnostics of TBM.

### Metagenomic next-generation sequencing and pyrosequencing {#sec3-5}

Next-generation sequencing has great potential as a method for rapidly identifying MTB genome and diagnosing drug resistance pattern[@ref49][@ref50]. Next-generation sequencing is capable of identifying genomes of many bacteria, fungi, parasites and viruses and can be of great help in establishing the exact diagnosis, when other tests are unrewarding[@ref51]. Pyrosequencing is a real-time technology for rapid sequencing of small segments of genomic DNA. This technique reliably detects mutations that confer antituberculosis drug resistance[@ref52]. Under the RNTCP, two laboratories have been designated to perform whole genome sequencing and pyrosequencing[@ref2].

Other tests {#sec1-5}
===========

 {#sec2-3}

### Adenosine deaminase {#sec3-6}

Adenosine deaminase (ADA) estimation, in cerebrospinal fluid, has long been used, as a simple and reliable test for differentiating TBM from other meningitis[@ref53][@ref54]. ADA is produced in all human cells; lymphoid tissues, particularly, lymphocytes dominantly produce this enzyme. It eliminates a molecule called deoxyadenosine, which is detrimental to lymphocytes. ADA is released by T cells during cell-mediated immune reaction against MTB. In a recent meta-analysis, ADA estimation was found valuable in TBM diagnosis[@ref55]. Sensitivity and specificity of ADA estimation were 89 and 91 per cent, respectively. The mean adenosine deaminase cerebrospinal fluid levels of ADA in CSF of TBM patients was 14.24 IU/l, non-tuberculous meningitis 7.92 IU/l and in other neurological diseases it was 2.32 IU/l. In pyogenic meningitis, mean ADA level was 8.22 IU/l[@ref55]. The most appropriate cut-off value for ADA levels is not precisely known. At a cut-off level of 2.0 IU/l, many TBM cases are missed, and higher cut-off levels are associated with severely decreased sensitivity[@ref56].

### Interferon-gamma release assays (IGRAs) {#sec3-7}

Interferon-gamma release assays (IGRAs) capitalises estimation of interferon-gamma released from T lymphocytes from MTB-infected patients when stimulated with MTB-specific antigens. IGRAs are rapid tests developed to identify latent tuberculosis infection. IGRAs were developed as an alternative for tuberculin skin test, and are not meant to diagnose active tuberculosis[@ref20].

IGRAs in TBM lack sufficient sensitivity and specificity to rely on. A meta-analysis observed that the pooled sensitivity of blood and CSF IGRAs were 78 and 77 per cent with 61 and 88 per cent specificity, respectively. Indeterminate results were noted in a large number of patients[@ref21][@ref57].

Lipoarabinomannan (LAM) {#sec1-6}
=======================

The LAM, a glycolipid, is a component of the mycobacterial cell wall. It has several immunomodulatory effects, like, interference with macrophage activation and antigen processing. LAM is released into the blood from metabolically active and disintegrating MTB. Urinary excretion is considered independent of the anatomical location of the infection. The detection of MTB LAM antigen in urine has also been used for the diagnosis of tuberculosis[@ref21].

LAM assay has been evaluated as a rapid diagnostic test for TBM[@ref23]. Unfortunately, LAM assay in the CSF lacks sufficient sensitivity and specificity. For example, in paediatric TBM patients LAM assay had a sensitivity of 4.8 per cent and a specificity of 93.1 per cent[@ref58]. In adult TBM patients, the sensitivity of LAM assay was only 22 per cent, and urine LAM assay was 24 per cent[@ref24]. The WHO currently does not recommend LAM assay for the diagnosis of any form of TB except, cases with HIV infection with low CD4 counts[@ref22].

Methods to increase yield of diagnostic testing {#sec1-7}
===============================================

 {#sec2-4}

### Invasive pulmonary sampling {#sec3-8}

In patients with possible and probable TBM, an active search for TB with invasive pulmonary samples has shown to increase the number of microbiological confirmations in TBM. Pulmonary sampling can be obtained with the help of computed tomography thorax, followed by bronchoscopy and bronchoalveolar lavage[@ref59].

### Large cerebrospinal fluid volume {#sec3-9}

A CSF volume more than 6 ml is associated with significantly higher yield of almost all microbiological confirmation tests[@ref60][@ref61]. A meta-analysis analyzed the impact of CSF volume on the diagnostic performance of Xpert MTB/RIF assay[@ref60]. Five studies reported the volume of CSF. Starting from the largest collection volume at 7 ml, the highest sensitivity was 85 per cent. If the CSF volume was 6 ml, the sensitivity decreased to 60 per cent[@ref60].

### Cerebrospinal fluid centrifugation {#sec3-10}

Centrifugation of CSF improves the sensitivity of all the tests. In a Cochrane review, pooled sensitivity in concentrated specimens was 74.8 per cent (15 studies, 2758 specimens) versus 66.2 per cent (12 studies, 905 specimens) in unconcentrated specimens. Pooled specificity in concentrated specimens was 98.3 versus 97.7 per cent in unconcentrated specimens[@ref60].

Does improved diagnostics reduce mortality? {#sec1-8}
===========================================

With the availability of better genotypic diagnostic tests, more number of suspected TBM can be microbiologically confirmed. Cresswell *et al*[@ref61], in a retrospective evaluation, noted that significantly increased number of microbiologically-confirmed TBM cases led to a marginal decrease in in-hospital mortality. In this study, microbiological confirmation increased from 3 to 41 per cent that led to a decline in the in-hospital mortality from 57 to 41 per cent.

Conclusion {#sec1-9}
==========

TBM continues to pose diagnostic challenges. Microbiological confirmation is not always possible. Latest genotypic tests are rapid and have additional capability to identify non-viable MTB bacilli. Unfortunately, genotypic tests do not have enough sensitivity to rule out meningeal tuberculosis. Xpert MTB/RIF test is now widely available in India but failed to demonstrate sufficient sensitivity in Indian patients. Xpert MTB/RIF Ultra, an advanced technology, though not available in India, is being considered a game-changer in the diagnosis of TBM. Physicians in India will have to rely on their clinical acumen till latest diagnostic technologies are available.
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